KYTX insider transaction filings
Kyverna Therapeutics, Inc. — 41 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-29. Screen KYTX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for KYTX between 2026-06-25 and 2026-09-23. The table below lists the most recent filings on record.
Recent Form 4 filings — Kyverna Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-29 | 4 | Aktar Mert — Director | Grant/award (A): 5,093 @ $0 · Grant/award (A): 20,582 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Shaw Christi — Executive Chairperson, Director | Tax withholding (F): 4,194 @ $8.59 | EDGAR |
| 2026-05-29 | 4 | Cohen Fred E — Director | Grant/award (A): 5,093 @ $0 · Grant/award (A): 20,582 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | CLARK IAN T — Director | Grant/award (A): 5,093 @ $0 · Grant/award (A): 20,582 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | SEIDENBERG BETH C — Director | Grant/award (A): 5,093 @ $0 · Grant/award (A): 20,582 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Martini Gregory S. — Chief Financial Officer | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Dac Nadia — Chief Commercial Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | GEHCHAN NAJI — See Remarks | Grant/award (A): 18,000 @ $0 · Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Biddle Warner Weston — Chief Executive Officer, Director | Grant/award (A): 58,000 @ $0 · Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | GRASSO MARC — Chief Financial Officer | Grant/award (A): 10,000 @ $0 · Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Miller Andrew Craig — Director | Grant/award (A): 11,006 @ $0 · Grant/award (A): 42,945 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | Emany Sravan Kumar — Director | Grant/award (A): 11,006 @ $0 · Grant/award (A): 42,945 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Pujols Mayobanex — Chief Technology Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | Shaw Christi — Executive Chairperson, Director | Grant/award (A): 30,000 @ $0 · Grant/award (A): 24,301 @ $0 · Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Westlake BioPartners Opportunity Fund I, L.P. — 10% owner Westlake BioPartners Opportunity GP I, LLC — 10% owner Westlake BioPartners Fund I, L.P. — 10% owner Westlake BioPartners GP I, LLC — 10% owner | Purchase (P): 133,333 @ $7.50 | EDGAR |
| 2025-12-22 | 4 | SEIDENBERG BETH C — Director | Purchase (P): 133,333 @ $7.50 | EDGAR |
| 2025-12-17 | 4 | Walker Karen Marie — Chief Technology Officer | Option exercise (M): 23,998 @ $4.83 · Sale (S): 23,998 @ $12.20 · Option exercise (M): 23,998 (derivative) @ $0 | EDGAR |
| 2025-07-01 | 4 | GRASSO MARC — Chief Financial Officer | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Aktar Mert — Director | Grant/award (A): 16,634 @ $0 · Grant/award (A): 65,351 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Shaw Christi — Director | Grant/award (A): 16,634 @ $0 · Grant/award (A): 65,351 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | CLARK IAN T — Director | Grant/award (A): 16,634 @ $0 · Grant/award (A): 65,351 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Cohen Fred E — Director, 10% owner | Grant/award (A): 16,634 @ $0 · Grant/award (A): 65,351 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | SPIEGELMAN DANIEL K — Director | Grant/award (A): 16,634 @ $0 · Grant/award (A): 65,351 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | SEIDENBERG BETH C — Director, 10% owner | Grant/award (A): 16,634 @ $0 · Grant/award (A): 65,351 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Biddle Warner Weston — Chief Executive Officer, Director | Grant/award (A): 332,500 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Jones Ryan Alexander — Chief Financial Officer | Grant/award (A): 12,000 @ $0 · Grant/award (A): 74,000 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Walker Karen Marie — Chief Technology Officer | Grant/award (A): 13,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Shaw Christi — Director | Grant/award (A): 38,679 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | GEHCHAN NAJI — See Remarks | Grant/award (A): 425,000 (derivative) @ $0 | EDGAR |
| 2024-10-24 | 4 | Aktar Mert — Director | Grant/award (A): 87,741 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | Biddle Warner Weston — Chief Executive Officer, Director | Grant/award (A): 2,579,259 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | Shaw Christi — Director | Grant/award (A): 66,592 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Walker Karen Marie — Chief Technology Officer | Option exercise (M): 9,636 @ $4.42 · Option exercise (M): 9,636 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | Jones Ryan Alexander — Chief Financial Officer | Option exercise (M): 10,870 @ $0.73 · Option exercise (M): 7,146 @ $0.73 · Option exercise (M): 10,870 (derivative) @ $0 · Option exercise (M): 7,146 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Vida Ventures, LLC — 10% owner Vida Ventures GP III, L.L.C. — 10% owner Vida Ventures III, L.P. — 10% owner Vida Ventures III-A, L.P. — 10% owner | Conversion (C): 4,523,924 · Purchase (P): 252,553 @ $22 · Purchase (P): 583 @ $22 · Conversion (C): 4,401,771 (derivative) @ $0 · Conversion (C): 8,830,901 (derivative) @ $0 · Conversion (C): 7,356,162 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Bain Capital Life Sciences Investors, LLC — 10% owner Bain Capital Life Sciences III General Partner, LLC — 10% owner Bain Capital Life Sciences Fund III, L.P. — 10% owner Bain Capital Life Sciences Opportunities III GP, LLC — 10% owner Bain Capital Life Sciences Opportunities III, LP — 10% owner | Conversion (C): 2,713,868 · Purchase (P): 450,000 @ $22 · Conversion (C): 12,351,087 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Westlake BioPartners Fund I, L.P. — 10% owner Westlake BioPartners GP I, LLC — 10% owner Westlake BioPartners Opportunity Fund I, L.P. — 10% owner Westlake BioPartners Opportunity GP I, LLC — 10% owner Harper Sean E — 10% owner | Conversion (C): 3,787,940 · Conversion (C): 735,984 · Conversion (C): 4,401,771 (derivative) @ $0 · Conversion (C): 8,830,901 (derivative) @ $0 · Conversion (C): 4,006,624 (derivative) @ $0 · Conversion (C): 3,349,538 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Cohen Fred E — Director, 10% owner | Conversion (C): 4,523,924 · Conversion (C): 4,401,771 (derivative) @ $0 · Conversion (C): 8,830,901 (derivative) @ $0 · Conversion (C): 7,356,162 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | SEIDENBERG BETH C — Director, 10% owner | Conversion (C): 3,787,940 · Conversion (C): 735,984 · Conversion (C): 4,401,771 (derivative) @ $0 · Conversion (C): 8,830,901 (derivative) @ $0 · Conversion (C): 4,006,624 (derivative) @ $0 · Conversion (C): 3,349,538 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | GILEAD SCIENCES, INC. — 10% owner | Conversion (C): 3,216,119 · Purchase (P): 910,000 @ $22 · Conversion (C): 6,890,744 (derivative) @ $0 · Conversion (C): 7,746,139 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Northpond Ventures III GP, LLC Northpond Ventures III, LP Rubin Michael P. | Conversion (C): 2,805,426 · Purchase (P): 450,000 @ $22 · Conversion (C): 12,767,776 (derivative) | EDGAR |
Recent 8-K events — Kyverna Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KYTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →